ClinicalTrials.gg
Sign In
Not yet recruitingNCT07817043MOTION-SepsisUpdated Sep 14, 2026

Microbiology Operations & Time Optimization in Sepsis

An observational study in Sepsis, Bloodstream Infection and Bacterial Infections, sponsored by University Medicine Greifswald. Not yet recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by University Medicine Greifswald · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Study summary

The goal of this study is to simulate turn-around times of blood cultures from blood culture collection to final communication of the result. The main objective is to develop a web-based tool that is able to simulate heterogeneous laboratory settings and to analyse the impact of infrastructure and opening hours on blood culture turn-around times.

Read the detailed description

will follow

02

Conditions studied

  • Sepsis
  • Bloodstream Infection
  • Bacterial Infections
  • Septic Shock
  • Bacteremia

Keywords

  • Sepsis
  • blood cultures
  • opening hours
  • infrastructure
  • microbiology
  • laboratory
  • simulation
03

In context

Sepsis

2,416 studies on the registry are indexed under Sepsis; 541 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 150 across 1,162 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

University Medicine Greifswald is the lead sponsor of 152 studies on the registry; 22 are open to participants now.

Browse University Medicine Greifswald studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

microbiological laboratories

Eligibility criteria

microbiological laboratories conducting blood culture analysis

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testlaboratory infrastructure

    will follow

06

What researchers measure

Primary outcomes

  1. Turn-around time

    Time frame: 4 weeks for the conduction of the simulation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 491 non-industry observational studies under Sepsis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 58. This study's planned 12 months is below that.

Counting every sponsor, half of 543 studies reached it within 27 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 14, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2028
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07817043
Lead sponsor
University Medicine Greifswald
Collaborators
Karolinska University Hospital
Responsible party
Christian S. Scheer, MD (Dr. med. Christian S. Scheer, University Medicine Greifswald) — Principal investigator
First posted
Sep 14, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Sep 14, 2026

Study contacts

Christian S Scheer, MD
Contact
christian.scheer@med.uni-greifswald.de
Evgeny A Idelevich, MD, Prof.
Contact
Evgeny.Idelevich@med.uni-greifswald.de

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Sepsis →

Other studies from this sponsor

University Medicine Greifswald →

Start the discussion